Form 4: Gossamer Bio Executive Acquires 440,000 Stock Options
SEC Form 4 Filing
Christian Waage, EVP of Tech Ops and Admin at Gossamer Bio, Inc., acquired 440,000 stock options on March 4, 2025.
Summary
- Christian Waage, an executive at Gossamer Bio, Inc., filed a Form 4 to report changes in beneficial ownership.
- On March 4, 2025, Waage acquired 440,000 stock options with an exercise price of $1.13.
- These options vest over time, with 25% vesting on March 4, 2026, and the remainder vesting monthly thereafter, contingent upon continuous service.
- The options expire on March 3, 2035.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of the stock option acquisition. |
| 03/04/2026 | Date when 25% of the stock options vest. |
| 03/03/2035 | Expiration date of the stock options. |
| 03/06/2025 | Date of the form filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.